ITIF/WHO collaboration for innovation, urging open trade, in combating coronavirus

19 May 2020
who_flag_big

The Information Technology and Innovation Foundation (ITIF), a Washington DC independent think tank focusing on science and technology policy, yesterday, at the 73rd World Health Assembly, joined a worldwide network of independent think tanks to issue a “ Joint Declaration on the Importance of Collaboration, Open Trade, and Innovation in Tackling COVID-19,” calling on governments to take a specific series of measures related to trade and innovation in order to save lives and prepare countries for future pandemics and public health challenges.

“International trade is vital for providing widespread access to medicines, medical devices, and protective equipment, as very few countries are self-sufficient in producing them,” said ITIF vice president for global innovation policy Stephen Ezell. “For this reason, governments should eschew placing tariffs on medical goods and further commit themselves to permanently reduce tariffs on medical supplies, devices, medicines, and vaccines via legally binding World Trade Organization commitments, such as the WTO Pharmaceutical Agreement and the Information Technology Agreement,” he added.

The declaration, signed by ITIF and 16 other members of the Global Trade and Innovation Policy Alliance (GTIPA), urges governments to:

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical